CR20220004A - Nuevos compuestos heterocíclicos - Google Patents
Nuevos compuestos heterocíclicosInfo
- Publication number
- CR20220004A CR20220004A CR20220004A CR20220004A CR20220004A CR 20220004 A CR20220004 A CR 20220004A CR 20220004 A CR20220004 A CR 20220004A CR 20220004 A CR20220004 A CR 20220004A CR 20220004 A CR20220004 A CR 20220004A
- Authority
- CR
- Costa Rica
- Prior art keywords
- heterocyclic compounds
- new heterocyclic
- compounds
- sup
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19185088 | 2019-07-09 | ||
| PCT/EP2020/069074 WO2021005034A1 (en) | 2019-07-09 | 2020-07-07 | New heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220004A true CR20220004A (es) | 2022-01-31 |
Family
ID=67220669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220004A CR20220004A (es) | 2019-07-09 | 2020-07-07 | Nuevos compuestos heterocíclicos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220242876A1 (https=) |
| EP (1) | EP3997096B1 (https=) |
| JP (1) | JP7649283B2 (https=) |
| KR (1) | KR20220034104A (https=) |
| CN (1) | CN114096545A (https=) |
| AR (1) | AR119376A1 (https=) |
| AU (1) | AU2020311584A1 (https=) |
| BR (1) | BR112021026899A2 (https=) |
| CA (1) | CA3145338A1 (https=) |
| CL (1) | CL2022000019A1 (https=) |
| CO (1) | CO2022000186A2 (https=) |
| CR (1) | CR20220004A (https=) |
| IL (1) | IL288987A (https=) |
| MX (1) | MX2022000243A (https=) |
| PE (1) | PE20220515A1 (https=) |
| PH (1) | PH12021553249A1 (https=) |
| TW (1) | TW202116781A (https=) |
| WO (1) | WO2021005034A1 (https=) |
| ZA (1) | ZA202110352B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| PE20211089A1 (es) | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
| WO2020104494A1 (en) | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| CN114269755A (zh) | 2019-09-12 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物 |
| CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014001946A (es) * | 2011-08-19 | 2014-03-27 | Merck Sharp & Dohme | Inhibidores del canal de potasio medularmente externo renal. |
| US9573961B2 (en) | 2012-12-19 | 2017-02-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2017087863A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| EP3571202B1 (en) * | 2017-01-23 | 2021-06-30 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
| JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| JP7257387B2 (ja) * | 2017-08-29 | 2023-04-13 | ハー・ルンドベック・アクチエゼルスカベット | スピロ環化合物並びにその作製及び使用方法 |
| WO2019134985A1 (en) * | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| MX2022000083A (es) * | 2019-07-03 | 2022-02-03 | Hoffmann La Roche | Inhibidores de monoacilglicerol lipasa (magl) heterociclicos. |
-
2020
- 2020-07-07 CN CN202080050165.3A patent/CN114096545A/zh active Pending
- 2020-07-07 AU AU2020311584A patent/AU2020311584A1/en not_active Abandoned
- 2020-07-07 CR CR20220004A patent/CR20220004A/es unknown
- 2020-07-07 PH PH1/2021/553249A patent/PH12021553249A1/en unknown
- 2020-07-07 JP JP2022500908A patent/JP7649283B2/ja active Active
- 2020-07-07 CA CA3145338A patent/CA3145338A1/en active Pending
- 2020-07-07 BR BR112021026899A patent/BR112021026899A2/pt not_active Application Discontinuation
- 2020-07-07 MX MX2022000243A patent/MX2022000243A/es unknown
- 2020-07-07 EP EP20740259.5A patent/EP3997096B1/en active Active
- 2020-07-07 WO PCT/EP2020/069074 patent/WO2021005034A1/en not_active Ceased
- 2020-07-07 KR KR1020227000611A patent/KR20220034104A/ko not_active Ceased
- 2020-07-07 PE PE2021002265A patent/PE20220515A1/es unknown
- 2020-07-08 TW TW109123050A patent/TW202116781A/zh unknown
- 2020-07-08 AR ARP200101928A patent/AR119376A1/es not_active Application Discontinuation
-
2021
- 2021-12-13 ZA ZA2021/10352A patent/ZA202110352B/en unknown
- 2021-12-14 IL IL288987A patent/IL288987A/en unknown
-
2022
- 2022-01-04 CL CL2022000019A patent/CL2022000019A1/es unknown
- 2022-01-06 US US17/569,749 patent/US20220242876A1/en active Pending
- 2022-01-13 CO CONC2022/0000186A patent/CO2022000186A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553249A1 (en) | 2023-02-27 |
| BR112021026899A2 (pt) | 2022-05-10 |
| EP3997096A1 (en) | 2022-05-18 |
| ZA202110352B (en) | 2022-08-31 |
| TW202116781A (zh) | 2021-05-01 |
| WO2021005034A1 (en) | 2021-01-14 |
| EP3997096C0 (en) | 2024-08-28 |
| CL2022000019A1 (es) | 2022-10-21 |
| IL288987A (en) | 2022-02-01 |
| CO2022000186A2 (es) | 2022-01-17 |
| PE20220515A1 (es) | 2022-04-07 |
| AR119376A1 (es) | 2021-12-15 |
| JP7649283B2 (ja) | 2025-03-19 |
| EP3997096B1 (en) | 2024-08-28 |
| KR20220034104A (ko) | 2022-03-17 |
| MX2022000243A (es) | 2022-02-03 |
| JP2022539604A (ja) | 2022-09-12 |
| US20220242876A1 (en) | 2022-08-04 |
| AU2020311584A1 (en) | 2022-01-20 |
| CA3145338A1 (en) | 2021-01-14 |
| CN114096545A (zh) | 2022-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4474017A3 (en) | New heterocyclic compounds | |
| PH12021551167A1 (en) | New heterocyclic compounds | |
| CR20210056A (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
| MX2020008894A (es) | Inhibidores de oxazin monoacilglicerol lipasa (magl). | |
| MX2023002224A (es) | Compuestos heterociclicos. | |
| CR20220004A (es) | Nuevos compuestos heterocíclicos | |
| MX2023012477A (es) | Compuestos heterociclicos. | |
| ZA202005326B (en) | Heteroaryl compounds as type ii irak inhibitors and uses hereof | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| MX2021002978A (es) | Lactamas biciclicas y metodos de uso de las mismas. | |
| PH12022550433A1 (en) | Heterocyclic compounds | |
| PH12022550471A1 (en) | Heterocyclic compounds | |
| PH12022550472A1 (en) | New heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| MY200641A (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
| EP4302827A3 (en) | Rapamycin analogs and uses thereof | |
| CR20230382A (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
| MX2020002449A (es) | Nuevos compuestos heterociclicos fungicidas. | |
| EP4706394A3 (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| MX2023009045A (es) | Derivados novedosos de pirimidin-2-il sulfonamida. | |
| MX2020006370A (es) | Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas. | |
| WO2021094505A8 (en) | Herbicidal compounds | |
| CR20200610A (es) | Nuevos derivados de isoxazolit éter como pan de gaba a alfa 5 | |
| MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. | |
| WO2018166993A3 (en) | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | |
| EP4647426A3 (en) | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, THEIR PREPARATION AND USE |